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Background: Anxiety disorders are prevalent and associated with poor prognosis in patients with coronary artery
disease (CAD). However, studies examining screening of anxiety disorders in CAD patients are lacking. In the
present study we evaluated the prevalence of anxiety disorders in patients with CAD and diagnostic utility of
self-rating scales for screening of anxiety disorders.
Methods: Five-hundred and twenty-three CAD patients not receiving psychotropic treatments at initiation of
rehabilitation program completed self-rating scales (Hospital Anxiety and Depression Scale or HADS; Spielberger
State-Anxiety Inventory or SSAI; and Spielberger Trait-Anxiety Inventory or STAI) and were interviewed for
generalized anxiety disorder (GAD), social phobia, panic disorder and agoraphobia (Mini-International
Neuropsychiatric Interview or MINI).
Results: Thirty-eight (7%) patients were diagnosed with anxiety disorder(s), including GAD (5%), social phobia (2%),
agoraphobia (1%) and panic disorder (1%). Areas under the ROC curve of the HADS Anxiety subscale (HADS-A), STAI
and SSAI for screening of any anxiety disorder were .81, .80 and .72, respectively. Optimal cut-off values for
screening of any anxiety disorders were ≥8 for the HADS-A (sensitivity = 82%; specificity = 76%; and positive
predictive value (PPV) = 21%); ≥45 for the STAI (sensitivity = 89%; specificity = 56%; and PPV = 14%); and ≥40 for the
SSAI (sensitivity = 84%; specificity = 55%; PPV = 13%). In a subgroup of patients (n = 340) scoring below the optimal
major depressive disorder screening cut-off value of HADS-Depression subscale (score <5), the HADS-A, STAI and
SSAI had moderate-high sensitivity (range from 69% to 89%) and low PPVs (≤22%) for GAD and any anxiety
disorders.
Conclusions: Anxiety disorders are prevalent in CAD patients but can be reliably identified using self-rating scales.
Anxiety self-rating scales had comparable sensitivities but the HADS-A had greater specificity and PPV when
compared to the STAI and SSAI for screening of anxiety disorders. However, false positive rates were high,
suggesting that patients with positive screening results should undergo psychiatric interview prior to initiating
treatment for anxiety disorders and that routine use of anxiety self-rating scales for screening purposes can increase
healthcare costs. Anxiety screening has incremental value to depression screening for identifying anxiety disorders.
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Anxiety disorders affect up to 20% of patients across dif-
ferent stages of coronary artery disease (CAD) [1-4].
Generalized anxiety disorder (GAD) is the most preva-
lent anxiety disorder with point prevalence rates ranging
from 5% [1,2] to 12% [3-5]. Other anxiety disorders are
less common in CAD patients [2-4]. Although, anxiety,
when compared to depression, has received significantly
less attention in CAD patients, but emerging data sug-
gest that anxiety disorders are associated with increased
risk for all-cause mortality and major adverse cardiac
events independently from disease severity, depression
and adverse health behaviors [1,2,5]. Anxiety symptoms
also predict poor clinical [6,7] and patient–centered out-
comes [8,9].
The American Heart Association has recently recom-
mended routine screening for depression in CAD patients
[10]. Screening for anxiety disorders was not included in
these recommendations despite the fact that anxiety disor-
ders are often under-recognized and untreated in cardiac
patients [11-13]. For example, a study in 74 patients
admitted for acute myocardial infarction (MI) within 72
hours after symptom onset found that healthcare pro-
viders failed to identify 69% of patients with elevated
symptoms of anxiety and 50% of patients with anxiety dis-
orders [11]. Another study in 158 stable heart failure pa-
tients found that 58% and 60% of patients with positive
screening results for depression and/or anxiety disorder(s)
on a telephone interview had a documented diagnosis of
depression and/or anxiety and received mental health
treatment, respectively [12]. On the other hand, up to 92%
of patients with a documented diagnosis of depression or
anxiety received mental health treatment, suggesting that
identification of psychiatric disorders in CAD patients im-
proves mental health treatment availability that could po-
tentially improve prognosis and quality of life of CAD
patients [12]. Poor identification of anxiety disorders can
be attributed to the fact that healthcare providers are more
concerned with management of physical symptoms and
rarely used standardized screening scales [13]. Further-
more, data regarding psychometric properties of anxiety
self-rating scales remain limited in CAD patients [13].
We and others have previously shown that Depression
subscale of the Hospital Anxiety and Depression Scale
(HADS-D) [14] and Beck Depression Inventory-II [15] had
acceptable psychometric properties for screening of depres-
sive disorders and for evaluation of depressive symptom se-
verity across different stages of CAD [16-19]. Recently,
Frasure-Smith and Lesperance demonstrated that Anxiety
subscale of the HADS (HADS-A) had acceptable sensitiv-
ity and specificity for screening of generalized anxiety dis-
order (GAD) in stable CAD patients two months after
acute coronary syndromes [2]. The Spielberger State-Trait
Anxiety Inventory was designed to evaluate anxiety aspersonality trait (Spielberger Trait Anxiety Inventory or
STAI) and as emotional state (Spielberger State Anxiety
Inventory or SSAI) [20]. In CAD patients, the STAI and
SSAI are widely used for evaluation of anxiety symptom
severity but screening properties of these instruments re-
main to be investigated [21,22].
The aims of this study were to establish the prevalence
of anxiety disorders in stable CAD patients undergoing
rehabilitation, and to evaluate the internal consistency
and psychometric properties of the HADS-A, STAI and
SSAI for screening of anxiety disorders.
Methods
Patients and procedure
In the period from October 2007 until December 2011
consecutive patients attending a cardiac rehabilitation
program at the Behavioral Medicine Institute of the
Lithuanian University of Health Sciences in Palanga,
Lithuania were considered for this study. In Lithuania,
patients are referred for cardiac rehabilitation within one
week after discharge from cardiology inpatient unit fol-
lowing treatment for acute coronary syndromes. Hence,
patients were included in this study approximately two
weeks after experiencing an episode of acute coronary
syndrome. Patients were not invited to the study if they
were older than 80 years of age, had severe medical co-
morbidities, unstable cardiovascular status, communica-
tion problems or did not speak Lithuanian fluently. A
total of 648 patients met the study criteria and agreed to
participate in the study. However, for the purpose of the
present report and in accordance with recent recom-
mendation for diagnostic accuracy studies of depression
scales, 125 (19%) patients receiving treatment with psy-
chotropic medication were not included in the analyses
[23]. Thus, our final study sample consisted of 523 pa-
tients. Data on personality related differences and on
evaluation of depression in this cohort of patients were
previously published elsewhere [17,24-28].
Within three days of admission all patients were evalu-
ated by study cardiologists for demographic characteristics,
New York Heart Association (NYHA) functional class [29],
hypertension, angina pectoris [30], obesity, previous inter-
ventional treatments for CAD (percutaneous coronary
intervention (PCI) or coronary artery bypass graft surgery),
current use of cardiac and psychotropic medication, and
histories of MI and diabetes mellitus. Hypertension was de-
fined as systolic blood pressure ≥ 140 mmHg and/or dia-
stolic blood pressure ≥ 90 mmHg. Patients with body mass
index ≥ 30 kg/m2 were considered obese. During the same
visit patients were evaluated for anxiety symptoms and de-
pression using the HADS [14], STAI, SSAI [20] and BDI-II
[15]. Scales were checked for missing items and patients
were asked to complete the missing items. On the next day
patients were interviewed for current psychiatric disorders
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Mental Disorders, 4th edition, Text revision (DSM-IV-TR)
criteria using the Mini International Neuropsychiatric
Interview (MINI) [31-33]. The interviewer was blind to
clinical characteristics, psychiatric histories, psychotropic
treatments and scores on anxiety and depression self-
rating scales. The interviewer was trained to administer
the MINI by study psychiatrist over two 120-minutes
training sessions. Two unclear diagnostic cases were
discussed with the training psychiatrist and included the
differentiation of GAD and major depressive episode
(MDE) from adjustment disorder due to acute cardiac
event.
The study and its consent procedures were approved
by the Ethics Committee for Biomedical Research at the
Lithuanian University of Health Sciences. A written in-
formed consent was obtained from each study patient.
Instruments
Diagnosis of anxiety disorder according to the MINI
was considered the gold standard [33]. Patients were
interviewed using all modules of the MINI, except for
antisocial personality disorder. For purposes of this
study, we used modules of the MINI pertaining current
GAD, current social phobia, current panic disorder,
current agoraphobia and current MDE. Patients were
not interviewed for histories of anxiety disorders. Each
module of the MINI consists of a screening question
that is followed by diagnostic questions. Administration
of the MINI takes from 2 to 20 minutes, depending on
presence and complexity of psychiatric disorder(s). As
per DSM-IV-TR criteria and MINI instructions, patients
with current MDE were not evaluated for GAD if symp-
toms of anxiety were limited exclusively to the depres-
sive episode. It is well documented that non-English
translations of the MINI, including Japanese [34], French
[35] and Portuguese [36], have acceptable validity against
other structured psychiatric interviews, including the
Structured Diagnostic Interview for DSM (SCID) [37].
Lithuanian version of the MINI was established by using
double-blind translation method and was approved by the
authors who developed the original version of the MINI
[32]. The MINI is widely used in commercial clinical trials
and for research purposes in Lithuania [17,38,39].
The HADS is comprised of two 7-item subscales of
depression (HADS-D) and anxiety (HADS-A) designed
to measure respective symptoms during the past week.
Each HADS item is rated from 0 to 3, with total score
ranging from 0 to 21 and with higher score indicating
more severe anxiety symptoms. It was originally pro-
posed that scores from 8 to 10 suggest, and scores ≥ 11
indicate probable anxiety and depressive disorder [14].
The HADS-A evaluates symptoms of GAD and panic
disorder [14]. The HADS is well-validated in Lithuaniafor screening of anxiety disorders and MDE in primary
care patients [38]. We have recently shown that the
HADS-D had adequate psychometric properties at a
cut-off value of ≥5 for screening of MDE in CAD pa-
tients [17]. Acceptable internal consistency (Cronbach’s
coefficient alpha = .83) and high sensitivity (91%) of the
HADS-A at a cut-off score of ≥8 for GAD were recently
reported in post-MI patients [2].
The Spielberger State-Trait Anxiety Inventory [20] is
comprised of two self-rating questionnaires: the SSAI
and STAI. Each questionnaire contains 20 statements
that are rated on 4-point Likert type scale. The SSAI is a
measure of how the patient is feeling at the particular
moment (state), whereas the STAI is a measure of the
patient’s general level of anxiety (trait). SSAI and STAI
items are divided into two groups: 10 items and 13
items, respectively, are formed to record the presence of
anxiety symptoms or traits and remaining items are
designed to record the absence of anxiety symptoms or
traits and are reverse scored [20]. Higher scores on both
scales indicate more anxiety symptoms. Scores on the
STAI and SSAI ≥ 30 suggest moderate anxiety and
scores ≥ 45 suggest severe anxiety [20]. Lithuanian trans-
lations of the SSAI and STAI are used for research pur-
poses for at least two decades in Lithuania [40].
The BDI-II is a 21-item self-rating scale that evaluates
for depressive symptom severity during the previous 2
weeks [15]. We have recently demonstrated the BDI-II
cut-off score of ≥14 had optimal psychometric properties
for screening of MDE in CAD patients undergoing re-
habilitation [17].
Statistical analyses
First, we examined psychometric properties of the HADS-
A, SSAI and STAI for screening of GAD only and for any
anxiety disorders. Patients were assigned to any anxiety
disorders group if they were positive for current DSM-IV-
TR diagnoses of GAD, social phobia, panic disorder and/
or agoraphobia on the MINI. We performed receiver
operating characteristics (ROC) curve analyses and calcu-
lated the areas under the ROC curve (AUCs). Cut-off
values with optimal balance between sensitivity and speci-
ficity were determined by visually assessing the ROC
curves. For each optimal cut-off value we computed sensi-
tivity (true-positive rate), specificity (true-negative rate),
positive predictive value (PPV; proportion of patients with
positive test results who were correctly diagnosed), nega-
tive predictive value (NPV; proportion of patients with
negative test results who were correctly diagnosed) and
accuracy. We also calculated 95% Confidence Intervals
(CI) for each value of sensitivity, specificity, PPV and NPV.
Next, we investigated how much screening for anxiety
disorders added incrementally to depression screening.
For these analyses, we excluded patients who screened
Table 1 Demographic, clinical and psychiatric
characteristics of 523 patients with coronary artery
disease
Demographic and clinical characteristics
Age, years, mean ± SD, median, IQR 57.5 ± 9.2; 57; 13
Gender, n (%)
Men 407 (78)
Women 116 (22)
NYHA class, n (%)
I 46 (9)
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off values of the HADS-D (≥5) and BDI-II (≥14) [17].
Subsequently, in the latter subgroups of patients, we in-
vestigated sensitivities, specificities, PPVs and NPVs of
the HADS-A, STAI and SSAI at optimal-cut off values
for screening of GAD and any anxiety disorders.
Data were analyzed using the PASW for Windows
(IBM Corporation, Chicago, Illinois). Data are expressed
as mean ± standard deviation and as median (interquar-
tile range; IQR) for quantitative variables, and as number
(percent) for qualitative variables.II 397 (76)
III 80 (15)
Hypertension, n (%) 419 (80)
Angina pectoris, n (%) 306 (59)
History of myocardial infarction, n (%) 363 (69)
Previous treatments, n (%)
Percutaneous coronary intervention 409 (78)
Coronary artery by-pass graft surgery 13 (3)
Diabetes mellitus, n (%) 45 (9)
Body mass index ≥30 kg/m2, n (%) 247 (47)
Psychiatric characteristics
Current MINI anxiety diagnoses, n (%):
Generalized anxiety disorder 26 (5)
Agoraphobia 7 (1)
Panic disorder 4 (1)Results
Baseline characteristics
Demographic, clinical and psychiatric characteristics of
523 study patients are presented in Table 1. Mean age of
study patients was 57.5 ± 9.2 years. The majority of pa-
tients were men (78%), were NYHA functional class II
(76%), had hypertension (80%), angina pectoris (59%),
history of acute MI (69%) and previous PCI (78%). Nine
percent of patients had diabetes and 47% were obese.
Thirty-eight (7%) patients were diagnosed with any
anxiety disorder. The most prevalent anxiety disorder
was GAD (5%), followed by social phobia (2%), agora-
phobia (1%) and panic disorder (1%). Thirty five percent
and 29% of patients were screened positive for MDE
according to the HADS-D (score ≥5) and BDI-II (score
≥14), respectively.Social phobia 8 (2)
Any anxiety disorder 38 (7)
Any anxiety disorder plus MDE 10/38 (26)
HADS-A score, mean ± SD, median, IQR 5.7 ± 3.6; 5; 5
STAI score, mean ± SD, median, IQR 44.1 ± 10.1; 44; 14
SSAI score, mean ± SD, median, IQR 39.0 ± 10.4; 39; 13
HADS-D score ≥5 183 (35)
BDI-II score ≥14 153 (29)
HADS-A - Anxiety subscale of the Hospital Anxiety and Depression Scale;
HADS-D - Depression subscale of the Hospital Anxiety and Depression Scale;
BDI-II – Beck Depression Inventory-II; MDE – major depressive episode; IQR-
interquartile range; NYHA - New York Heart Association; SSAI - Spielberger
State Anxiety Inventory; STAI - Spielberger State Anxiety Inventory.Screening for anxiety disorders
AUCs for the HADS-A, STAI and SSAI for screening of
GAD were at levels of .85, .82 and .74, respectively
(Table 2). Detailed psychometric properties of the
HADS-A, STAI and SSAI at optimal cut-off values for
screening of GAD are presented in Table 2. Specifically,
optimal cut-off values for screening of GAD were ≥8 for
the HADS-A (sensitivity = 92%, specificity = 75% and
PPV = 16%), ≥45 for the STAI (sensitivity = 92%, specifi-
city = 55% and PPV = 10%) and ≥40 for the SSAI (sensi-
tivity = 89%, specificity = 54% and PPV = 9%).
With regards to screening of any anxiety disorders, the
AUCs for the HADS-A, STAI and SSAI were at levels of
.81, .80 and .72, respectively (Table 3). Table 3 demon-
strates that optimal cut-off values for screening of any
anxiety disorder were the same as for screening of GAD
only. Specifically, optimal cut-off values were ≥8 for the
HADS-A (sensitivity = 82%, specificity = 76% and PPV =
21%), ≥45 for the STAI (sensitivity = 89%, specificity =
56% and PPV = 14%) and ≥40 for the SSAI (sensitivity =
84%, specificity = 55% and PPV = 13%). Sensitivities and
specificities of anxiety self-rating scales across different
cut-off values for screening of GAD and any anxiety dis-
order are presented in Additional file 1: Table S1 and S2.Incremental value of anxiety screening
In a subgroup of patients who scored <5 on the HADS-D
(i.e., screened negative for MDE; n = 340), the HADS-A,
STAI and SSAI at optimal cut-off values had moderate to
high sensitivity (range from 69% to 89%) and specificity
(range from 67% to 88%) but low PPVs (range from 7% to
22%) for GAD and any anxiety disorders (Table 4). Simi-
larly, in a subgroup of patients screened negative for MDE
according to the BDI-II (score <14; n = 370), the HADS-
A, STAI and SSAI had moderate to high sensitivity (range
from 50% to 80%) and specificity (range from 66% to
Table 2 Psychometric properties at optimal cut-off values of self-rating anxiety scales for screening of generalized
anxiety disorder in coronary artery disease patients (n = 523)
Cut-off scores N (%) Sensitivity,% (95% CI) Specificity,% (95% CI) PPV,% (95% CI) NPV,% (95% CI) Accuracy,% AUC (95% CI)
Hospital anxiety and depression scale – anxiety subscale
≥ 7 203 (39) 92 (73–99) 64 (60–68) 12 (8–17) 99 (98–100) 65 .85 (.76-.93)
≥ 8 148 (28) 92 (73–99) 75 (71–79) 16 (11–23) 99 (98–100) 76
≥ 9 100 (19) 69 (48–85) 84 (80–87) 18 (11–27) 98 (96–99) 83
Spielberger trait anxiety inventory
≥ 44 262 (50) 92 (73–99) 52 (48–57) 9 (6–13) 99 (97–100) 54 .82 (.75-.89)
≥ 45 246 (47) 92 (73–99) 55 (51–60) 10 (6–14) 99 (97–100) 57
≥ 46 229 (44) 85 (64–95) 58 (54–63) 10 (6–14) 99 (96–100) 60
Spielberger state anxiety inventory
≥ 39 267 (51) 89 (69–97) 51 (46–55) 9 (6–13) 99 (96–100) 53 .74 (.66-.82)
≥ 40 251 (48) 89 (69–97) 54 (50–59) 9 (6–14) 99 (97–100) 56
≥ 41 226 (43) 81 (60–93) 59 (54–63) 9 (6–14) 98 (96–99) 60
Optimal cut-off value in bold.
AUC - area under the receiver operating curve; CI – confidence interval; NPV- negative predictive value; PPV - positive predictive value.
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any anxiety disorders.
Discussion
In patients with CAD undergoing cardiac rehabilitation,
the prevalence of anxiety disorders, especially GAD, was
high. Anxiety self-rating scales had comparable sensitiv-
ities, but the HADS-A had better specificities for screen-
ing of GAD and any anxiety disorders when compared
with the STAI and SSAI. However, positive predictive
values were low of all anxiety self-rating scales analyzed
in the present study. Addition of anxiety screening to
depression screening had incremental value for identifi-
cation of anxiety disorders.Table 3 Psychometric properties at optimal cut-off values of
disorders in coronary artery disease patients (n = 523)
Cut-off score N (%) Sensitivity,% (95% CI) Specificity,% (95% CI
Hospital anxiety and depression scale – anxiety subscale
≥ 7 203 (39) 87 (71–95) 65 (60–69)
≥ 8 148 (28) 82 (65–92) 76 (72–80)
≥ 9 100 (19) 66 (49–80) 85 (81–88)
Spielberger trait anxiety inventory
≥ 44 262 (50) 89 (74–97) 53 (48–57)
≥ 45 246 (47) 89 (74–97) 56 (52–61)
≥ 46 229 (44) 84 (68–93) 59 (55–64)
Spielberger state anxiety inventory
≥ 39 267 (51) 84 (68–93) 52 (47–56)
≥ 40 251 (48) 84 (68–93) 55 (50–59)
≥ 41 226 (43) 76 (59–88) 59 (55–64)
Optimal cut-off value in bold.
AUC - area under the receiver operating curve; CI – confidence interval; NPV- negatPrevalence of anxiety disorders in our cohort corre-
sponds to previous studies. For example, similar preva-
lence rate of anxiety disorders was reported by Frasure-
Smith and Lesperance in stable post-MI patients [2].
Specifically, they reported that 5% of their patients had
current GAD; 2% had panic disorder and <1% had social
phobia according to the Structured Clinical Interview
for the DSM [2,41]. Another recent study found that
10% of stable CAD patients met GAD criteria in the past
year according to the Diagnostic Interview Schedule for
the DSM-IV [5]. Parker with colleagues, in patients with
acute coronary syndromes, found higher prevalence
rates of GAD (12%) and social phobia (9%) and similar
prevalence rates of agoraphobia (2%) and panic disorderself-rating anxiety scales for screening of any anxiety
) PPV,% (95% CI) NPV,% (95% CI) Accuracy,% AUC (95% CI)
16 (12–22) 98 (96–99) 67 .81 (.74-.89)
21 (15–29) 98 (96–99) 76
25 (17–35) 97 (95–98) 83
13 (9–18) 98 (96–100) 53 .80 (.73-.87)
14 (10–19) 99 (96–100) 56
14 (10–19) 98 (95–99) 59
12 (8–17) 98 (95–99) 54 .72 (.64-.79)
13 (9–18) 98 (95–99) 57
13 (9–18) 97 (94–99) 61
ive predictive value; PPV - positive predictive value.
Table 4 Psychometric properties at optimal cut-off values for generalized anxiety disorder and any anxiety disorder
screening in patients with negative depression screening results
Cut-off score N (%) Sensitivity,% (95% CI) Specificity,% (95% CI) PPV,% (95% CI) NPV,% (95% CI)
HADS-D score <5, n = 340
Generalized anxiety disorder
HADS-A≥ 8 49 (14) 89 (51–99) 88 (83–91) 16 (8–10) 100 (98–100)
STAI≥ 45 104 (31) 89 (51–99) 71 (66–76) 8 (4–15) 100 (97–100)
SSAI≥ 40 118 (35) 89 (51–99) 67 (61–72) 7 (3–13) 100 (97–100)
Any anxiety disorder
HADS-A≥ 8 49 (14) 69 (41–88) 88 (84–91) 22 (12–37) 98 (96–99)
STAI≥ 45 104 (31) 87 (58–98) 72 (67–77) 13 (71–21) 99 (97–100)
SSAI≥ 40 118 (35) 81 (54–95) 68 (62–73) 11 (6–18) 99 (96–100)
BDI-II score <14, n = 370
Generalized anxiety disorder
HADS-A≥ 8 45 (12) 80 (30–99) 89 (85–92) 9 (3–22) 100 (98–100)
STAI≥ 45 110 (30) 60 (17–93) 71 (66–75) 3 (1–8) 99 (97–100)
SSAI≥ 40 126 (34) 60 (17–93) 66 (61–71) 2 (1–7) 99 (97–100)
Any anxiety disorder
HADS-A≥ 8 45 (12) 50 (20–80) 89 (85–92) 11 (4–25) 98 (96–99)
STAI≥ 45 110 (30) 70 (35–92) 71 (66–76) 6 (3–13) 99 (96–100)
SSAI≥ 40 126 (34) 50 (20–80) 66 (61–71) 4 (1–9) 98 (95–99)
BDI-II – Beck Depression Inventory-II; CI – confidence interval; HADS -A – Hospital Anxiety and Depression scale – Anxiety subscale; HADS -D – Hospital Anxiety and
Depression scale – Depression subscale NPV- negative predictive value; PPV - positive predictive value.
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tic Interview [3,42]. In patients awaiting coronary revas-
cularization procedure, Tully and Penninx also reported
greater prevalence rates of MINI diagnoses of GAD
(10%), agoraphobia (4%) and social phobia (3%) [4].
These data suggest that the prevalence of anxiety disor-
ders can be different across different populations of
CAD patients. Hence, large epidemiological studies
evaluating the prevalence of anxiety disorders in CAD
patients diagnosed using well-validated and reliable in-
struments are needed.
The HADS-A had superior psychometric properties
for screening of GAD and any anxiety disorders when
compared to the STAI and SSAI. Specifically, although
at optimal cut-off values all three anxiety scales had
similar sensitivities for screening of GAD and any anx-
iety disorders, but the HADS-A had greater specificities
and PPVs when compared with the STAI and SSAI.
However, confidence intervals for sensitivities were wide
and can be explained by small numbers of cases. Hence,
further studies in larger samples of CAD patients and
meta-analysis of currently published anxiety screening
studies in CAD patients should be undertaken in order
to provide with more reliable estimates of optimal cut-
off values of anxiety screening scales.
At cut-off value of ≥ 8 the HADS-A yielded optimal
psychometric properties for screening of GAD and anyanxiety disorders. Similar sensitivity (91%) and lower
specificity (61%) of the HADS-A at cut-off value of ≥8
for GAD was previously reported in stable CAD patients
[2]. Marginal differences in psychometric properties of
the HADS-A in the latter study when compared to our
results can be partially explained by different gold stan-
dards used and by different time-frame of psychiatric
evaluation with respect to acute coronary syndromes.
Furthermore, in our study, at cut-off value of ≥8 the
HADS-A had acceptable psychometric properties for
screening of any anxiety disorder and GAD only,
suggesting that CAD patients scoring ≥8 on the HADS-
A should undergo psychiatric evaluation for all anxiety
disorders, rather than for GAD alone.
Optimal cut-off values of the STAI and SSAI were ≥45
and ≥40, respectively, for GAD and for any anxiety dis-
order. A recent study in 100 pregnant women reported
optimal cut-off value of the STAI and SSAI of ≥ 40 with
sensitivities and specificities of about 80% for both scales
for screening of current MINI diagnoses of panic disorder,
agoraphobia, social phobia, GAD, and posttraumatic stress
disorder [43]. Lower sensitivities and greater specificities
of the STAI and SSAI in pregnant women can be attrib-
uted to different patients’ populations and to different
anxiety disorders evaluated across studies. Nonetheless, to
the best of our knowledge, ours was the first study evaluat-
ing psychometric properties of the SSAI and STAI for
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and our results remain to be replicated in independent
samples of CAD patients.
It should be noted that the HADS-A, STAI and SSAI had
low PPVs, suggesting that these scales are overly inclusive
and the majority of CAD patients with positive screening
results will not meet the DSM-IV-TR criteria for anxiety
disorders. A study by Frasure-Smith and Lesperance in
post-MI patients, found similar PPV (12%) of the HADS-A
for screening of GAD [2]. Also, low PPVs of the HADS-D
for screening of major depressive disorder were previously
reported in CAD patients [17,18]. These findings suggest
that somatic symptoms can interfere with subjective
evaluation of mental distress using self-rating scales and
that significant proportion of CAD patients suffer from
mental distress that does not reach the DSM-IV-TR sever-
ity threshold criteria [44,45]. Low PPVs of anxiety self-
rating-scales can be partially explained by low prevalence
rate of anxiety disorders and by possible residual and/or
subclinical symptoms of mood or anxiety disorders in the
subgroup of patients without current anxiety disorders.
However, anxiety prevalence rates in our cohort corres-
pond to the existing literature and subclinical symptoms
of psychological distress are highly prevalent in CAD pa-
tients. The major goal of anxiety screening is differenti-
ation of patients with anxiety disorder(s) from those with
subclinical symptoms of psychological distress.
High false-positive rates suggest that mental health
treatment should not be initiated based solely on screen-
ing results and patients with positive screening results
should be always referred for detailed psychiatric evalu-
ation by mental health specialists. High false positive rates
also indicate that routine use of the HADS-A, STAI and
SSAI for anxiety disorder screening purposes can over-
stretch healthcare resources. On the other hand, high
specificities and high NPVs of the HADS-A, STAI and
SSAI suggest that anxiety disorders are highly unlikely
among CAD patients scoring below the recommended
threshold values.
Our results also provided with evidence that anxiety
screening can have incremental value to depression
screening. Specifically, we found that depression screen-
ing can miss a substantial proportion of patients suffer-
ing from anxiety disorder, but these patients can be
identified with anxiety screening. A two-step diagnostic
algorithm can be particularly useful in the light of high
false positive rates, is currently recommended for de-
pression screening [10] and should be investigated for
anxiety screening purposes in CAD patients.
There remains a debate in the literature whether there is
enough evidence to justify systematic screening for mental
disorders in CAD patients. Specifically, although system-
atic screening for depression has been recommended in
CAD patients [10], but these guidelines were challengedmainly because there is not a single randomized controlled
trial demonstrating benefits of such screening for clinical
and mental health outcomes [23,46-49]. In addition, costs
and safety of depression screening warrants additional re-
search [23,47]. Similar limitations apply to anxiety dis-
order screening, since there are no studies demonstrating
clinical benefits, safety and cost-effectiveness of such prac-
tice. Thus, prior to recommending routine screening of
anxiety disorders in CAD patients there is a need for well
conducted randomized trials clearly demonstrating that
systematic anxiety screening is safe, cost-effective and car-
ries clear clinical benefits, such as reduction of anxiety
symptoms and improved clinical outcomes.
Exclusion of patients with advanced age, severe co-
morbidities or unstable cardiovascular status can limit
generalizability of our results. Also, our results cannot
be applied to patients with acute coronary syndromes
because we studied stable CAD patients admitted for
cardiac rehabilitation. In addition, future studies should
consider detailed evaluation for psychiatric histories
since residual symptoms of mood and anxiety disorders
in patients without current anxiety disorder can poten-
tially impact the screening results. Finally, test-retest re-
liability of anxiety self-rating scales was not investigated.
However, rehabilitation offers excellent opportunity for
identification of mental distress when there are no life-
threats that could potentially intervene with psycho-
logical assessments. The major strengths of our study in-
clude large sample size and the use of structured clinical
psychiatric interview.
Conclusions
In sum, anxiety disorders are prevalent in CAD patients
and can be reliably identified using self-rating scales. All
anxiety self-rating scales analyzed in the present report
have similar sensitivities, but the HADS-A has superior
specificities and PPVs when compared to the STAI and
SSAI for screening of anxiety disorder in CAD patients
undergoing rehabilitation. However, patients with posi-
tive screening results should undergo comprehensive
psychiatric evaluation in order to establish diagnosis and
initiate optimal treatment strategy. Anxiety screening
has incremental value to depression screening for identi-
fying anxiety disorders. Finally, studies demonstrating
safety, cost-effectiveness and clinical benefits of anxiety
screening are warranted prior to recommending rou-
tine screening of anxiety disorders outside of research
protocols.
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